American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

PURPOSE To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. METHODS The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. RESULTS Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in pre-analytic variables, thresholds for positivity, and interpretation criteria. RECOMMENDATIONS The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.

[1]  W. McGuire,et al.  Therapy for cancer of the breast. Current status of steroid hormone receptors. , 1979, The Western journal of medicine.

[2]  K. Jirström,et al.  High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients , 2006, Clinical Cancer Research.

[3]  M. Hammond,et al.  Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. , 2010, Archives of pathology & laboratory medicine.

[4]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[5]  A. Gown,et al.  Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. , 2004, American journal of clinical pathology.

[6]  N. Sneige,et al.  Estrogen Receptor Analysis for Breast Cancer: Current Issues and Keys to Increasing Testing Accuracy , 2005, Advances in anatomic pathology.

[7]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[8]  W. McGuire,et al.  Progesterone receptors as a prognostic factor in stage II breast cancer. , 1983, The New England journal of medicine.

[9]  D. Hayes.  Markers of endocrine sensitivity , 2008, Breast Cancer Research.

[10]  J. Ioannidis,et al.  Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. , 2006, Journal of the National Cancer Institute.

[11]  B. Rasmussen,et al.  Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. , 1986, Cancer research.

[12]  D. Barnes,et al.  Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening , 2000, Journal of clinical pathology.

[13]  G. Anderson,et al.  Expanding priorities--confronting chronic disease in countries with low income. , 2007, The New England journal of medicine.

[14]  V. Jensen,et al.  Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer. , 1995, Journal of clinical pathology.

[15]  D. Barnes,et al.  Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.

[16]  C. Adebamowo,et al.  Immunohistochemical and molecular subtypes of breast cancer in Nigeria , 2008, Breast Cancer Research and Treatment.

[17]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[18]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[19]  Edith A Perez,et al.  Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Reid,et al.  Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay , 1990, Histopathology.

[21]  G. Francis,et al.  Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program , 2007, Journal of Clinical Pathology.

[22]  R. Gelber,et al.  Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Allred,et al.  Development of Standard Estrogen and Progesterone Receptor Immunohistochemical Assays for Selection of Patients for Antihormonal Therapy , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[24]  B. Jasani,et al.  Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. , 2008, American journal of clinical pathology.

[25]  C. Redmond,et al.  Treatment of primary breast cancer with chemotherapy and tamoxifen. , 1981, The New England journal of medicine.

[26]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[27]  C. Osborne,et al.  HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[28]  R. Gelber,et al.  Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. , 2006, Journal of the National Cancer Institute.

[29]  M. Ellis,et al.  Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. , 2009, JAMA.

[30]  J M Esteban,et al.  Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. , 1994, Journal of cellular biochemistry. Supplement.

[31]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[32]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Müller-Hermelink,et al.  Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. , 2002, American journal of clinical pathology.

[34]  D. Horsfall,et al.  A simple index using video image analysis to predict disease outcome in primary breast cancer , 1999, International journal of cancer.

[35]  J. Yahalom,et al.  [Treatment of metastatic breast cancer]. , 1986, Harefuah.

[36]  M. Dowsett,et al.  A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women , 2009, Breast Cancer Research and Treatment.

[37]  J. Cuzick,et al.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Mallon,et al.  Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. , 2002, Breast.

[39]  B. Djulbegovic,et al.  Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding , 1990, Journal of clinical laboratory analysis.

[40]  D. Arber.  Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[41]  I. Ferri,et al.  Computer-assisted immunocytochemical determination of breast cancer steroid receptors. Frozen sections vs paraffin sections. , 2001, Breast.

[42]  C. Jordan.  Historical perspective on hormonal therapy of advanced breast cancer. , 2002, Clinical therapeutics.

[43]  E B Cox,et al.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.

[44]  W. McGuire,et al.  Hormone receptors in primary and advanced breast cancer. , 1980, Clinics in endocrinology and metabolism.

[45]  E. Jensen,et al.  Estrogen-receptor interactions in target tissues. , 1967, Archives d'anatomie microscopique et de morphologie experimentale.

[46]  B. Kennedy,et al.  Massive estrogen administration in premenopausal women with metastatic breast cancer , 1962, Cancer.

[47]  Jack Cuzick,et al.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Werner,et al.  Influence of Fixation, Antibody Clones, and Signal Amplification on Steroid Receptor Analysis , 1998 .

[49]  V. McCormack,et al.  Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women , 2009, Breast Cancer Research.

[50]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  R. Gelman,et al.  Estrogen receptor assay: interlaboratory and intralaboratory variations in the measurement of receptors using dextran-coated charcoal technique: a study sponsored by E.C.O.G. , 1981, European journal of cancer.

[52]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[53]  A. Haddow,et al.  Influence of Synthetic Oestrogens on Advanced Malignant Disease , 1944, British medical journal.

[54]  D. Barnes,et al.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.

[55]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  K. Hirakawa,et al.  Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy , 2004, Breast cancer.

[57]  C. Redmond,et al.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[59]  Maria Sjöberg,et al.  Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. , 2005, Molecular endocrinology.

[60]  W. McGuire,et al.  Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1975, Science.

[61]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[62]  H. Yamashita,et al.  Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer , 2006, Breast cancer.

[63]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[64]  D. Oxley,et al.  Precision in estrogen and progesterone receptor assays. Results of the first CAP pilot survey. , 1982, American journal of clinical pathology.

[65]  I. Nenci,et al.  Detection and dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique. , 1976, Journal of steroid biochemistry.

[66]  M. Dowsett,et al.  Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  A. Trentham-Dietz,et al.  Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[68]  Clive R Taylor,et al.  Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[69]  T. Kuopio,et al.  Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. , 2005, Anticancer research.

[70]  D. DeMets,et al.  Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[72]  M. Lippman.  An assessment of current achievements in the systemic management of breast cancer , 1984, Breast Cancer Research and Treatment.

[73]  A. Scharl,et al.  Immunohistochemical detection of progesterone receptor in formalin-fixed and paraffin-embedded breast cancer tissue using a monoclonal antibody , 2006, Archives of Gynecology and Obstetrics.

[74]  Karen A Gelmon,et al.  Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  W. McGuire.  Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.

[76]  J. Wittliff,et al.  Establishment of uniformity in steroid receptor analyses used in cooperative clinical trials of breast cancer treatment. , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[77]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  J. Horiguchi,et al.  Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer. , 2005, Oncology reports.

[79]  R. Gelber,et al.  Facilitating consensus by examining patterns of treatment effects. , 2009, Breast.

[80]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[81]  N. Goldstein,et al.  Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. , 2003, American journal of clinical pathology.